Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosis

Abstract

Background: Umbilical cord mesenchymal stem cells (UCMSCs) have been demonstrated to have good therapeutic effects in the treatment of HBV-related liver diseases. However, the therapeutic effect of UCMSCs on HBV-related liver failure and liver cirrhosis and the variations in the efficacy of UCMSCs after different treatment courses remain poorly understood. Therefore, this study was designed to answer these two questions. Methods: This was an observational study that retrospectively considered a 3-year period during which 513 patients who received stem cell infusion and met the criteria of hepatic failure and liver cirrhosis were identified from the databases of the Third Affiliated Hospital of Sun Yat-sen University. The eligible patients were categorized into the liver failure group and liver cirrhosis group. The two groups were divided into different subgroups according to the duration of stem cell therapy. In the liver failure group, group A received more than 4 weeks and group B received less than 4 weeks of stem cell therapy. In the liver cirrhosis group, patients who received more than 4 weeks of stem cell therapy belonged to group C, and the patients in group D received less than 4 weeks of stem cell therapy. The patients were followed up for 24 weeks. The demographics, clinical characteristics, biochemical factors, and model for end-stage liver disease (MELD) scores were recorded and compared among different groups.

The assessment of mesenchymal stem cells therapy in acute on chronic liver failure and chronic liver disease: a systematic review and meta-analysis of randomized controlled clinical trials

“…Another distinct advantage is the decreased alloreactivity due to a low expression of class I and class II human leukocyte antigen [ 16 ]. Clinical studies have shown that UC-MSCs infusion significantly improved liver function in patients with decompensated liver cirrhosis [ 17 ] and increased the survival rates of patients with ACLF [ 8 , 13 , 18 , 19 ].…”

General consensus on multimodal functions and validation analysis of perinatal derivatives for regenerative medicine applications

“…Different reports highlighted as injection of UC-WJ-MSC in patients with chronic liver disorders or steatohepatitis ameliorate transaminase levels and lipid profile, reduces bilirubin and hyperglycemic profile, resulting in improved MELD score and overall survival (see ( Shahrbaf et al, 2022 ) for revision of such clinical studies). Beneficial clinical support offered by perinatal cells has been ascribed to repeated infusion rather than one single infusion ( Jia et al, 2020 ), in line with results offered by 3 decades of hepatocyte transplantation ( Gramignoli et al, 2015 ). Another source of perinatal MSC, amniotic membrane, has been described as instrumental to attenuate Kupffer autophagy and prevent Stellate activation ( Shahrbaf et al, 2022 ).…”

Extraembryonic Mesenchymal Stromal/Stem Cells in Liver Diseases: A Critical Revision of Promising Advanced Therapy Medicinal Products

“…Additionally, they can extend the overall survival rate in long-term follow-up [ 120 ]. Furthermore, endurance and extended donor cells have been ascribed to beneficial multiple infusion of UC-MSC rather than single injection [ 121 ]. In the context of other non-fibrotic chronic liver disorders, UC-MSC administration in models of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) resulted in hyperglycemia decrement, reversal in transaminase escalation, improvement in lipid profile (such as triglyceride, low-density lipoprotein, or total cholesterol).…”